Posts Tagged: "Healthcare"

While the COVID-19 pandemic has changed every aspect of our lives, digital transformation in healthcare has accelerated above others. The pandemic has changed the healthcare delivery paradigm from human to digital platforms faster than Klaus Schwab could have imagined. In 2016, the World Economic Forum chairman coined the phrase “Fourth Industrial Revolution,” envisioning the combination of fourth industrial-era technologies in hardware, software, and biology, or cyber-physical systems. These new technologies, leveraging advances in communication, connectivity, and computing power, would usher in a more efficient way to live, work, and socialize. Who knew how the horrific circumstances triggered by a global pandemic could accelerate an evolution that might have taken 20 years and condensed into a single year. Healthcare has gone digital, and there is no going back now.

Is Congress really going to do anything useful with respect to lowering drug prices? When the question is presented that way the answer almost seems painfully obvious. Of course not. The question is just how bad they will mess things up, and will they destroy the incentive to innovate as they attempt to seek a very worthwhile solution for the problem of growing costs for healthcare. Unfortunately, the political climate in the United States has increasingly become more circus and circumspect than bold and visionary. It is better to do something entertaining and memorable that plays to the crowd than to go about the business of governing the country, not just for the moment, but for the future. And the political structures in place create outright gerrymandering that practically ensure the overwhelming percentage of Representatives have more to fear from a primary challenge than from a contender in the general election. It is no wonder nothing truly useful can get accomplished in Washington, DC.

Once we go down a path of government price controls and compulsory licensing we will have foregone opportunities for other, more rational policy choices and will soon find ourselves in a race to the bottom. Of course, making prescription drugs more affordable must be an important, shared goal. But the solutions we pursue cannot risk choking off America’s innovative ecosystem that leads the world in discovering new cures and treatments. As Nobel laureate and NIH Director Harold Varmus said in 1995, one must first have a new drug to price before one can worry about how to price it.  Letting our federal government import foreign price controls and expropriate patents is not the way to go about it.

This week is a very busy one on Capitol Hill where hearings on various subjects related to technology and innovation are concerned. The House of Representatives will hold hearings on Chinese threats in innovation supremacy as well as nuclear energy and the American Innovation Act of 2018. The Senate will host hearings focused on quantum information science, consumer data privacy and reducing health care costs through innovation. Both houses will hold hearings to look at activities going on at the nation’s space exploration agency, NASA.

Karin Seegert studied pharmacy and received her PhD from the University of Munich in 1985. Following several years working in R&D in industry, she joined the EPO in 1991. During her time at the EPO, she has worked as Examiner and then beginning in 2002 as Director in the pharmaceutical area and as Director in Patent Administration. In 2010, Karin became Principal Director with responsibility for various technical fields, mainly in Electro Physics and Chemistry, before being appointed as Chief Operating Officer in 2017 she was leading the cluster Technical Chemistry (TeC).

The price-tag for non-innovative drug patents, such as these second-wave Restasis patents, is substantial. Indeed, one cannot help but question Allergan’s true motivations for attempting to evade PTAB scrutiny of these patents by reliance on Tribal Immunity based on its deal with the St. Regis Mohawk Tribe. The PTAB, unlike the examiner corps, does have the ability to consider rebuttal expert testimony, and is thus not-so handicapped in its capacity to vet drug patents of questionable validity, with aplomb.

Barcode reading solutions provider Code Corporation of Salt Lake City, UT, announced that it had filed antitrust actions against engineering conglomerate Honeywell International (NYSE:HON) at both the U.S. International Trade Commission and in the Eastern District of Texas. Code, which is seeking an injunction on the importation and sale of barcode readers marketed by Honeywell for the healthcare industry, alleges that Honeywell engaged in a campaign to mislead distributors about the legitimacy of Code’s barcode reader products as part of an effort to monopolize that market.

Because the production costs of these medical devices and pharmaceuticals are so high, millions of people around the world are unable to obtain necessary healthcare. For example, as of 2014, close to seventy percent of all cardiac pacemaker sales occurred in the United States and Europe, while several countries in Africa and Asia have absolutely no access to pacemakers. In order to respond to this problem, research scientists have begun developing low-cost medical technologies and using intellectual property rights to give people in developing countries access to adequate healthcare.